The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial).
 
Cengiz Inal
No Relationships to Disclose
 
Bilal Piperdi
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
Other Relationship - Merck
 
Steven M. Keller
Speakers' Bureau - Lilly
 
Balazs Halmos
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Roche Pharma AG
Research Funding - Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Healthcare Ventures; Incyte; Merck; Mirati Therapeutics; Novartis; Pfizer; Roche Pharma AG
 
Mark Stoopler
No Relationships to Disclose
 
Sewanti Atul Limaye
No Relationships to Disclose
 
Benjamin Philip Levy
No Relationships to Disclose
 
Bryan J. Schneider
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
 
Mimi Kim
No Relationships to Disclose
 
Jessica Sides
No Relationships to Disclose
 
Roman Perez-Soler
Honoraria - AstraZeneca; Clovis Oncology; Lilly; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Roche Pharma AG
Speakers' Bureau - Boehringer Ingelheim; Genentech; Lilly
 
Haiying Cheng
No Relationships to Disclose